Belite Bio (BLTE) director sells 1,100 ADS via Rule 10b5-1 plan

Rhea-AI Filing Summary

Belite Bio director Wan-Shan Chen sold 1,100 American depositary shares in an open-market transaction. The sale took place on April 9, 2026 at an average price of $180.4301 per ADS. After this sale, Chen directly holds 9,096 ADS. Each ADS represents one ordinary share of Belite Bio. The transaction was executed under a Rule 10b5-1 trading plan that Chen adopted on December 23, 2025, indicating the sale was pre-arranged rather than timed at discretion.

Insider Trade Summary 10b5-1

Net Seller: 1,100 shares ($198,473)

Net Sell 1 txn

Insider Chen Wan-Shan

Role Director

Sold 1,100 shs ($198K)

Type	Security	Shares	Price	Value
Sale	American depositary share	1,100	$180.4301	$198K

Holdings After Transaction: American depositary share — 9,096 shares (Direct)

Footnotes (1)

1. Each American depositary share represents one ordinary share, par value US$0.0001 per share, of the issuer. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/23/2025.

Key Figures

Shares sold: 1,100 ADS Sale price: $180.4301 per ADS Shares held after transaction: 9,096 ADS +1 more

4 metrics

Shares sold 1,100 ADS Open-market sale on April 9, 2026

Sale price $180.4301 per ADS Average price for the 1,100 ADS sale

Shares held after transaction 9,096 ADS Direct ownership after April 9, 2026 sale

ADS to ordinary share ratio 1 ADS = 1 ordinary share Each ADS represents one ordinary share, par value US$0.0001

Key Terms

American depositary share, Rule 10b5-1 trading plan, open-market sale

3 terms

American depositary share financial

"Each American depositary share represents one ordinary share, par value US$0.0001 per share"

An American Depositary Share (ADS) is a U.S.-listed certificate that represents a specified number of shares in a foreign company, held by a custodian bank; it works like a receipt that allows U.S. investors to buy and trade foreign equity on American exchanges without dealing with another country’s markets. Investors care because ADSs make foreign stocks easier to access, improve liquidity and settlement in dollars, and can affect dividend payments, voting rights and regulatory oversight compared with buying the underlying foreign shares directly.

Rule 10b5-1 trading plan regulatory

"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chen Wan-Shan

(Last) (First) (Middle)

12750 HIGH BLUFF DRIVE, SUITE 475

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BELITE BIO, INC [ BLTE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
American depositary share(1)	04/09/2026		S(2)		1,100	D	$180.4301	9,096	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Each American depositary share represents one ordinary share, par value US$0.0001 per share, of the issuer.

2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/23/2025.

	/s/ Wan-Shan Chen	04/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Belite Bio (BLTE) disclose in this Form 4?

Belite Bio reported that director Wan-Shan Chen sold 1,100 American depositary shares in an open-market transaction on April 9, 2026 at $180.4301 per ADS. This filing updates investors on Chen’s latest shareholding position and disposition activity.

At what price did the Belite Bio (BLTE) director sell shares?

The director’s 1,100 American depositary shares were sold at an average price of $180.4301 per ADS. This price reflects the execution level for the reported open-market sale on April 9, 2026, as disclosed in the Form 4 filing.

How many Belite Bio (BLTE) shares does Wan-Shan Chen hold after the sale?

Following the sale, Wan-Shan Chen directly holds 9,096 American depositary shares of Belite Bio. This post-transaction balance is explicitly stated in the Form 4 and shows Chen’s remaining direct ownership after the 1,100 ADS disposition.

Was the Belite Bio (BLTE) insider sale made under a Rule 10b5-1 plan?

Yes. The Form 4 states that the sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Wan-Shan Chen on December 23, 2025. Such plans pre-arrange trading activity, reducing the significance of the exact transaction timing.

What does each Belite Bio (BLTE) American depositary share represent?

Each Belite Bio American depositary share represents one ordinary share of the issuer, with a par value of US$0.0001 per share. This one-to-one relationship between ADS and ordinary shares is explicitly described in the Form 4 footnotes.